drugset / Trial / NCT00415909
TALL-104 and Gleevec in Chronic Myelogenous Leukemia Patients
NaSingle-groupOpen-labelTreatment
Summary
Objectives: * To determine the response rate and duration of response with combination of TALL-104 cells and imatinib mesylate (IM) therapy in patients with chronic myelogenous leukemia in chronic phase, that have not achieved, or have lost, adequate response to IM. * To determine the toxicity of the combination of TALL-104 cells and IM therapy in this patient population.
Timeline
- Start
- 2006-12
- Primary completion
- 2013-05
- Completion
- 2013-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TALL-104 | Unknown | 109 cells | Intravenous |
| Background | Imatinib | Small molecule | 100 mg | Oral |
| Background | Imatinib | Small molecule | 400 mg | Oral |